Last reviewed · How we verify
NCT07196124
BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma
EARLY_PHASE1 trial testing BCMA/GPRC5D CAR-T in Multiple Myeloma Refractory in 12 participants. Not yet recruiting.
9 October 2028
Quick facts
| Lead sponsor | Guangzhou Bio-gene Technology Co., Ltd |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 10 October 2025 |
| Primary completion | 9 October 2028 |
| Estimated completion | 9 December 2028 |
Drugs / interventions tested
- BCMA/GPRC5D CAR-T — full drug profile →
Conditions studied
- Multiple Myeloma Refractory — all drugs for Multiple Myeloma Refractory →
Sponsor
Guangzhou Bio-gene Technology Co., Ltd — full company profile →
Who can join
Adults 18 to 85, any sex, with Multiple Myeloma Refractory. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single-arm, multicenter clinical trial of dose escalation and dose expansion.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07196124
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Myeloma Refractory
Currently open trials in the same condition.
- NCT07096778 — Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07477912 — Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma · Phase 1, PHASE2 · recruiting
Other Guangzhou Bio-gene Technology Co., Ltd trials
Trials by the same sponsor.
- NCT07195617 — Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Mult · NA · not yet recruiting
- NCT07196111 — BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors · EARLY_PHASE1 · not yet recruiting
- NCT07123662 — γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant · EARLY_PHASE1 · not yet recruiting
- NCT07152210 — Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced C · NA · recruiting
- NCT07152236 — Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid Tumors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07196124 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangzhou Bio-gene Technology Co., Ltd
- Last refreshed: 29 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07196124.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing